The Australian multicentre double‐blind comparative study of remoxipride and thioridazine in schizophrenia

@article{Keks1994TheAM,
  title={The Australian multicentre double‐blind comparative study of remoxipride and thioridazine in schizophrenia},
  author={Nicholas A Keks and John J. McGrath and Tim J R Lambert and S. V. Catts and K. S. Vaddadi and Graham D. Burrows and F. Varghese and Tom George and Harry Hustig and Peter Burnett and Kristin Kerr and Anthony Zorbas and Christine Hill and Terry Stedman and Gordon Johnson and B. Leibert and David L. Copolov and M. Mackenzie and C. Fischer Dillenbeck},
  journal={Acta Psychiatrica Scandinavica},
  year={1994},
  volume={90}
}
A double‐blind, randomized study of parallel group design comparing remoxipride and thioridazine (dose range 150–600 mg/day of either drug) was undertaken at 11 Australian centres. A total of 144 patients (remoxipride = 73, thioridazine = 71) with DSM‐III‐R schizophrenia or schizophreniform disorder commenced the study, and 89 patients (remoxipride = 45, thioridazine = 44) completed the 6 weeks of the trial. The mean daily doses at last rating were 404 mg (remoxipride) and 378 mg (thioridazine… 
Observational, open-label, prospective multicenter study of sexual function in patients starting treatment with aripiprazole.
TLDR
During the 3 months of treatment with aripiprazole, an overall improvement in sexual performance is observed, with a quicker recovery in men than in women, although recovery was similar in both at the end of treatment.
Thioridazine for schizophrenia.
TLDR
Although there are shortcomings, there appears to be enough consistency over different outcomes and periods to confirm that thioridazine is an antipsychotic of similar efficacy to other commonly used antipsychotics for people with schizophrenia.
Remoxipride versus thioridazine in the treatment of first episodes of schizophrenia in drug‐naive patients: A case for specific, low potency D2 antagonists
Remoxipride, a substituted benzamide, is a selective D2 antagonist with an atypical neuroleptic profile. Previous studies have demonstrated its antipsychotic efficacy against haloperidol and, more
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
TLDR
Some SGAs are more efficacious than FGAs, and, therefore,SGAs are not a homogeneous group, as suggested by consensus panel recommendations.
A meta-analysis of the efficacy of second-generation antipsychotics
TLDR
Some SGAs are more efficacious than FGAs, and, therefore,SGAs are not a homogeneous group, as suggested by consensus panel recommendations.
New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis
TLDR
New generation drugs were moderately more efficacious than low-potency antipsychotics, largely irrespective of the comparator doses used, and potential advantages in efficacy of the new generation drugs should be a factor in clinical treatment decisions to use these rather than conventional drugs.
Minimizing the non‐extrapyramidal side‐effects of antipsychotics
  • N. Keks
  • Medicine
    Acta psychiatrica Scandinavica. Supplementum
  • 1996
TLDR
New drugs, such as risperidone, are well tolerated, with fewer side‐effects, and should now be considered as a first‐line option.
From first to second generation antipsychotics
As late as 1993, 85% of psychotic inpatients at a major university psychiatric referral centre in the United States were found to be receiving antipsychotic drugs that had been available for some
Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.
TLDR
In animals, remoxipride has minimal cataleptic effects at doses that block dopamine agonist-induced hyperactivity and these findings are predictive of antipsychotic activity with a low likelihood of extrapyramidal symptoms.
Risperidone (Risperdal): clinical experience with a new antipsychosis drug.
TLDR
Compared to older neuroleptics, pharmacoeconomic studies have shown that use of risperidone is associated with reduced hospitalisation and direct cost savings, and a recent study found equivalent efficacy between ris peridone and clozapine for treatment-resistant patients.
...
1
2
3
...

References

SHOWING 1-10 OF 30 REFERENCES
A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia
TLDR
Remoxipride seemed to be as effective as haloperidol, had a lower frequency of side effects, and was used safely in the dose range 150–600 mg/day.
A double‐blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia
TLDR
Treatment‐emergent extrapyramidal checklist symptoms (hypokinesia, rigidity and tremor) were statistically significantly more frequent and more severe during haloperidol than during remoxipride treatment despite a statistically significantly higher concurrent use of anticholinergic drugs in the hal operidol group.
A double‐blind comparative study of remoxipride and haloperidol in acute schizophrenia.
TLDR
The clinical efficacy was similar in both groups as judged by Present State Examination (PSE) profile and Brief Psychiatric Rating Scale (BPRS) ratings, and several adverse symptoms occurred significantly more frequently during treatment with haloperidol than with remoxipride, particularly where extrapyramidal symptoms were concerned.
A double‐blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia
TLDR
Treatment‐emergent extrapyramidal symptoms (Simpson and Angus rating) occurred statistically significantly more frequently and were more severe during haloperidol than during remoxipride CR treatment despite a statistically significantly higher concurrent use of anticholinergic drugs in the hal operidol group.
Remoxipride and haloperidol in schizophrenia: a double‐blind multicentre study.
TLDR
Severe extrapyramidal side effects in the haloperidol group and clinical ineffectiveness in the remoxipride group were the most frequent reasons for premature discontinuation of treatment.
Clinical profile of remoxipride ‐ a combined analysis of a comparative double‐blind multicentre trial programme
TLDR
Remoxipride seems to have a clinical profile characterized by antipsychotic efficacy in acute schizophrenia, apparently equal to that of haloperidol, and good tolerability in being non‐sedative and with low incidences of extrapyramidal, autonomic, and endocrine symptoms.
A double‐blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders
TLDR
The antipsychotic effect of remoxipride was compared to that of haloperidol in a randomized double‐blind study with parallel group design and the two drugs seemed to be equally efficacious, though the tolerability profile favoured remxipride.
A double‐blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia
TLDR
There was no statistically significant between‐drug difference in improvement in mental state, as measured by the Brief Psychiatric Rating Scale, although the trend favoured thIORidazine; global assessment of illness severity at the last rating also favoured thioridazine.
Remoxipride and haloperidol in the acute phase of schizophrenia: a double‐blind comparison
TLDR
Remoxipride has an advantage over haloperidol in respect to extrapyramidal side effects and is as effective an antipsychotic as haloperidsol, according to the results.
A controlled dose‐ranging study of remoxipride and haloperidol in schizophrenia ‐ a Canadian multicentre trial
TLDR
The general I safety profile of remoxipride as assessed from clinical chemistry, haematology, and cardiovascular variables suggests that remoxIPride in the dose ranges studied can be used safely for the treatment of schizophrenic patients.
...
1
2
3
...